[ad_1]
A new vaccine against coronavirus infection (Corona 19) developed by British pharmaceutical companies AstraZeneca and the University of Oxford. Photo = Reuters
Amid growing doubts about the new vaccine against coronavirus infection (Corona 19) being developed by British pharmaceutical companies AstraZeneca and the University of Oxford, USA, it is drawing attention by delaying the expected time of approval of the vaccine.
On the 30th (local time), according to foreign media such as Reuters, Montseff Slawi, executive director of the US Corona 19 vaccine development program, ‘Ultrafast Operation’, related to the AstraZeneca vaccine, “If all goes well, the use of The emergency in the United States will probably be in April. I hope it is approved, “he said.
This is a schedule that has been delayed at least two months from previous projections from the United States government. Earlier this month, Slawi predicted that AstraZeneca would apply for emergency use to the US Food and Drug Administration (FDA) in February of next year.
The US political outlet Politico pointed out that the delay in the expected time to approve the AstraZeneta vaccine was due to questions about the effect.
If the vaccine is inoculated with half the dose first and a full dose is added after a month, the preventive effect reaches 90%.
Over the course of the clinical trial, some participants received only half of the first dose due to error by the researchers. However, like other vaccines, when the full dose was normally administered twice, the preventive effect was reduced to 62%.
The average prevention rate was only 70.4%. This is lower than that of Pfizer-Bioentech (95%) and Modena (94.5%).
“It is important to note that for Americans, one vaccine has a 95% prevention rate, while the other vaccine is ‘X%’ (unknown),” Slawy said. “It is not the sum of different clinical trials with different programs and different materials.” We need specific and clear numbers. “
He also noted that the preventive effect of the AstraZeneca vaccine in older people was “practically little known.” This is because the elderly rarely participated in existing clinical trials.
Currently, the United States government has ordered 300 million doses of the AstraZeneca vaccine.
Meanwhile, the UK government approved the emergency use of the AstraZeneca vaccine for the first time in the world. It is the second approval of the vaccine in the UK, which previously approved the world’s first urgent use of the Pfizer vaccine.
Reporter Chae Sun-hee [email protected]
Ⓒ Hankyung.com prohibits unauthorized reproduction and redistribution
